Fri, May 18, 2012
Thu, May 17, 2012
Wed, May 16, 2012
Tue, May 15, 2012
[ Tue, May 15th 2012 ] - Market Wire
CryoLife to Acquire Hemosphere
Mon, May 14, 2012
Sun, May 13, 2012
Sat, May 12, 2012
Fri, May 11, 2012
Thu, May 10, 2012
Wed, May 9, 2012
Tue, May 8, 2012
Mon, May 7, 2012
Sat, May 5, 2012
Fri, May 4, 2012

The Law Firm of Levi &;; Korsinsky Notifies Investors With Losses on Their Investment in Chelsea Therapeutics Interna


//health-fitness.news-articles.net/content/2012/ .. -investment-in-chelsea-therapeutics-interna.html
Published in Health and Fitness on Friday, May 11th 2012 at 12:11 GMT by Market Wire   Print publication without navigation


May 11, 2012 15:01 ET

Upcoming Deadline: The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in Chelsea Therapeutics International Ltd. of Class Action Lawsuit and the Deadline of June 4, 2012 to Seek a Lead Plaintiff Position

NEW YORK, NY--(Marketwire - May 11, 2012) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Western District of North Carolina on behalf of investors who purchased Chelsea Therapeutics International Ltd. ("Chelsea" or the "Company") (NASDAQ: [ CHTP ]) stock between November 3, 2008 and March 28, 2012.

For more information, click here: [ http://zlk.9nl.com/chelsea-therapeutics-international-chtp ]. There is no cost or obligation to you.

The complaint alleges that Chelsea made a series of materially false and misleading statements regarding the safety and efficacy of the drug Northera and the likelihood of its approval by the U.S. Food and Drug Administration ("FDA"). On February 13, 2012, Chelsea disclosed that the FDA had raised questions regarding the size and duration of its clinical trials for Northera. Furthermore, the FDA indicated that three deaths were potentially related to the drug. As a result of the aforementioned, shares of Chelsea stock declined more than 37 percent. Then on March 28, 2012, the Company announced that their New Drug Application for Northera was rejected by the FDA. Upon this news, Chelsea shares fell more than 28 percent, to close at $2.62 per share on March 29, 2012.

If you suffered a loss in Chelsea you have until June 4, 2012 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (877) 363-5972, or visit [ http://zlk.9nl.com/chelsea-therapeutics-international-chtp ].

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.



Publication Contributing Sources